InSilicoTrials was founded in 2017 by Luca Emili with the goal of revolutionizing the drug and medical device development process through computational modeling. The company provides a cloud-based platform where pharma companies and med-tech developers can conduct virtual clinical trials, expediting the research process and reducing costs. “We’re here to disrupt how clinical trials are conducted by making them faster, safer, and more affordable,” Emili states. By simulating complex biological interactions, InSilicoTrials enables researchers to predict drug efficacy and side effects without physical trials. This approach has gained traction as a way to improve safety while adhering to regulatory standards, positioning InSilicoTrials as a pioneer in the emerging field of digital clinical research.